At position 5q31.1, squeezed between the DNA-repair gene RAD50¹¹ RAD50
RAD50 double-strand break repair protein; at this locus the gene's introns house regulatory elements controlling adjacent cytokine genes and the cytokine gene IL13²² IL13
Interleukin-13; a Th2 cytokine secreted by mast cells, basophils, and activated CD4+ T cells that drives IgE class switching, mucus hypersecretion, and smooth-muscle hyperresponsiveness, sits one of the most replicated immune-regulation loci in the human genome. GWAS studies have repeatedly flagged this region — designated 5q31 (RAD50-IL13 and IL4) — as a major determinant of total serum IgE levels and susceptibility to the full spectrum of atopic march³³ atopic march
the stereotyped progression from early-childhood eczema through food allergy, then asthma, then allergic rhinitis; driven by a shared Th2-skewed immune baseline that successive allergen exposures progressively unmask conditions. rs2040704 is an intronic variant in this regulatory hub — the G allele tags a chromatin state that amplifies Th2 cytokine output, raising IgE and lowering the threshold for allergic sensitization at every stage of the march.

The Mechanism

The intergenic space between RAD50 and IL13 is not empty. It contains the TH2 locus control region (TH2-LCR)⁴⁴ TH2 locus control region (TH2-LCR)
a cluster of DNase I hypersensitive sites (RHS4–RHS7) that act as long-range enhancers coordinating simultaneous IL-4, IL-5, and IL-13 transcription in activated Th2 cells; analogous to the beta-globin LCR — a collection of regulatory enhancer elements (RHS4–RHS7) that loop chromosomally to simultaneously activate IL-4, IL-5, and IL-13 when a T cell commits to the Th2 lineage. The rs2040704 G allele sits within this control region and tags a regulatory haplotype that alters DNA methylation at the IL13 promoter and modulates the expression of both IL13 and IL4 in an allele-specific manner — as demonstrated by Schieck et al. (2014), who showed allele-specific methylation differences at the TH2-LCR element RHS7⁵⁵ allele-specific methylation differences at the TH2-LCR element RHS7
Schieck M et al. Allergy 2014; rs2240032 in RHS7 shows allele-dependent methylation in cord blood and at 4.5 years, influencing downstream IL13 promoter methylation tracking from cord blood through early childhood.

When the enhancer hub is in the more active state tagged by the G allele, T cells that encounter allergens produce higher pulses of IL-13 and IL-4. IL-13 then acts directly on airway epithelium and smooth muscle — bypassing the IgE-mast-cell axis — to drive mucus hypersecretion, goblet-cell metaplasia, and smooth-muscle hyperresponsiveness⁶⁶ mucus hypersecretion, goblet-cell metaplasia, and smooth-muscle hyperresponsiveness
Wills-Karp & Chiaramonte Curr Opin Pulm Med 2003; mouse models showed IL-13 alone, without eosinophils or IgE, reproduces all hallmarks of allergic asthma. Simultaneously, IL-4 drives B-cell class switching to IgE. Higher ambient IgE sensitizes mast cells systemically, lowering the allergen threshold for urticaria, food reactions, and nasal symptoms — the allergic phenotype spreads across organ systems.

The Evidence

The 5q31 RAD50/IL13 locus is one of only a handful of immune-regulation loci with genome-wide significance for total serum IgE in multiple large cohorts. A comprehensive genome-wide association study of severe asthma by Li et al. (2010)⁷⁷ Li et al. (2010)
Li X et al. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J Allergy Clin Immunol 2010 — 473 severe asthma cases and 1,892 controls — identified multiple significant SNPs in the RAD50-IL13 region, with the leading hit rs2244012 (intronic in RAD50) reaching P=3.04×10⁻⁷. The TH2 locus control region 3' of RAD50 was separately implicated by imputed variants, placing rs2040704's neighborhood at the mechanistic heart of this signal.

Fine-mapping by Sharma et al. (2014)⁸⁸ Sharma et al. (2014)
Sharma V et al. Fine-mapping of IgE-associated loci 1q23, 5q31, and 12q13 using 1000 Genomes Project data. Allergy 2014 in more than 1,300 German children confirmed 5q31 (RAD50-IL13 and IL4) as one of three major determinants of total serum IgE. Critically, they demonstrated that carrying risk alleles at all three loci — 5q31, 1q23 (FCER1A, the high-affinity IgE receptor), and 12q13 (STAT6) — elevates IgE risk fourfold, establishing that the 5q31 signal is most clinically meaningful when interpreted in the context of the broader atopic genetic landscape.

Cross-ethnic replication came from a Chinese Han study by Jiang et al. (2017)⁹⁹ Jiang et al. (2017)
Jiang XY et al. Asian Pac J Allergy Immunol 2017 of 3,013 atopic dermatitis cases and 5,483 controls, which confirmed a 5q31 RAD50/IL13 signal (rs2158177, a neighboring variant in strong LD, OR=1.15, P=1.08×10⁻³) for atopic dermatitis. The IL13 coding variant rs20541 — which produces the Gln144Arg amino acid change that reduces IL-13's affinity for its decoy receptor IL-13Rα2 and increases bioavailability — was independently confirmed as an atopic dermatitis risk variant by Lee et al. (2020)¹⁰¹⁰ Lee et al. (2020)
Lee E et al. Ann Allergy Asthma Immunol 2020 in 1,252 cases and 2,064 controls (P<0.001 in pilot, replicated). This distinct coding variant at the same locus converges on the same pathway: more effective IL-13 signaling.

The review by Potaczek & Kabesch (2012)¹¹¹¹ Potaczek & Kabesch (2012)
Potaczek DP, Kabesch M. Clin Exp Allergy 2012 contextualizes rs2040704's locus as one of six major genomic determinants of IgE regulation, alongside FCER1A, STAT6, IL4RA, TNFRSF13C, and PYCARD. Variants at 5q31 account for IgE variation driven primarily by Th2 cytokine production capacity — a distinct mechanism from FCER1A (receptor density) or IL4RA (receptor signaling efficiency).

Practical Implications

The G allele at rs2040704 does not diagnose allergy — it lowers the threshold at which allergen exposure tips into sensitization and sustained allergic inflammation. The most actionable implications concern early detection of atopic march progression and immune modulation strategies targeted at the IL-4/IL-13 axis.

Children with the GG genotype and early eczema have elevated biological risk for progression to food allergy and asthma — early allergen introduction protocols and barrier management become particularly relevant. Adults with the G allele who have never developed overt atopy may still carry subclinically elevated IgE that sensitizes them to new allergen exposures (occupational, pet, or seasonal) faster than non-carriers.

The therapeutic relevance is also increasing: biologics targeting this exact pathway — dupilumab (anti-IL-4Rα, blocks both IL-4 and IL-13 signaling), tralokinumab (anti-IL-13), and cendakimab — are now licensed for atopic dermatitis and/or asthma. G allele carriers who develop refractory atopic disease are biologically well-matched to this drug class, since the upstream genetic fault is in IL-13/IL-4 production rather than IgE receptor density or downstream signaling efficiency.

Interactions

rs2040704 at the 5q31 locus interacts multiplicatively with rs2228570/rs731236 (VDR) — vitamin D receptor variants that modulate Th2/Treg balance — and with rs20541 (IL13 R130Q), the coding variant ~23 kb downstream that determines IL-13 bioavailability independently of this regulatory variant. The combination of elevated IL-13 production (this locus) and reduced IL-13 clearance (rs20541 G allele, which reduces affinity for the decoy receptor) is a mechanistically coherent double hit for sustained Th2 inflammation.

Carriers who also have FCER1A rs2427827 or IL4RA rs1801275 risk alleles show the fourfold IgE elevation documented by Sharma et al. — a compound atopic signature where production, clearance, receptor density, and receptor signaling are all shifted toward the allergic pole.

Most people have heard of MTHFR, but the folate cycle runs on two tracks: the cytoplasmic pathway (where MTHFR operates) and the mitochondrial pathway, where MTHFD1L ¹¹ Methylenetetrahydrofolate dehydrogenase 1-like; the mitochondrial counterpart to the cytoplasmic MTHFD1 enzyme does the foundational work. MTHFD1L converts mitochondrial 10-formyl-THF into formate, which then crosses into the cytoplasm to fuel purine synthesis, thymidylate production, and ultimately the methylation cycle that generates S-adenosylmethionine²² S-adenosylmethionine
SAM: the universal methyl donor used in hundreds of cellular reactions. When MTHFD1L function is altered, the cytoplasmic folate pathway is starved of raw material even when dietary folate appears adequate.

rs2073067 is an intronic variant in MTHFD1L, located on chromosome 6q25.1. Because it falls within an intron, it does not directly change the enzyme's amino acid sequence. Instead, it likely tags a regulatory or splicing haplotype that modulates how much functional enzyme is produced or how efficiently the mitochondrial one-carbon pathway runs.

The Mechanism

MTHFD1L is a monofunctional enzyme that catalyzes a single step: the conversion of 10-formyl-THF to formate using the reversible reaction in the mitochondrial matrix. This formate serves as the primary source of cytoplasmic one-carbon units in most cell types. Without it, the methylation cycle loses throughput, homocysteine can accumulate, and purine synthesis — essential for dividing cells — is impaired.

Mouse models provide the starkest evidence of this pathway's importance: complete Mthfd1l deletion³³ complete Mthfd1l deletion
Momb et al., PNAS 2013 — all Mthfd1l-null embryos exhibited craniorachischisis and exencephaly causes universal neural tube defects (craniorachischisis and exencephaly), and these defects are partially rescued by maternal formate supplementation — confirming that reduced formate output, not simply folate deficiency, underlies the pathology. In humans, a separate MTHFD1L splicing variant (rs3832406) that alters the ratio of long to short transcripts is independently associated with neural tube defect risk⁴⁴ is independently associated with neural tube defect risk
Parle-McDermott et al., Hum Mutat 2009.

The rs2073067 G allele is intronic and likely tags a haplotype affecting MTHFD1L expression or splicing efficiency. Studies show MTHFD1L genetic variation influences both plasma homocysteine and global genomic methylation⁵⁵ plasma homocysteine and global genomic methylation
Wernimont et al., 2011 — MTHFD1L showed pleiotropy for both phenotypes across 330 SNPs in 52 folate-pathway genes, consistent with reduced mitochondrial one-carbon output feeding back to impair cytoplasmic methylation capacity.

The Evidence

rs2073067 was first identified in a GWAS of late-onset Alzheimer's disease⁶⁶ GWAS of late-onset Alzheimer's disease
Naj AC et al. PLoS Genetics 2010 — discovery + replication cohorts totaling ~1,800 cases and 2,500 controls that used MTHFD1L as a chromosome 6 locus providing genetic evidence for folate-pathway abnormalities in neurodegeneration. The primary lead SNP was rs11754661, but rs2073067 showed nominally significant association (P=0.03) as part of the same locus.

A replication study in Northern Han Chinese⁷⁷ replication study in Northern Han Chinese
Ma XY et al. J Alzheimers Dis 2012, n=1,189 found that rs2073067 showed a strikingly protective effect in APOE ε4 carriers specifically (OR = 0.40, p < 0.001), suggesting the variant modulates Alzheimer's risk in a genetic background sensitive to folate-homocysteine metabolism. The haplotype containing rs2073067 and rs11754661 ("AC") conferred increased risk overall (OR = 1.73). This heterogeneity — protective in one allelic context, risk-increasing in another — is characteristic of complex LD patterns in intronic regulatory variants.

The folate-pathway connection is mechanistically plausible: elevated homocysteine is a well-established risk factor for cognitive decline and Alzheimer's disease, and MTHFD1L variation influencing formate output would propagate through homocysteine re-methylation efficiency to affect long-term neurological health.

At the population level, the G allele frequency is approximately 37% in Europeans and 22% in East Asians, making the GG genotype present in roughly 10-12% of most populations — a substantial minority with potential benefit from targeted B-vitamin support.

Practical Implications

Because rs2073067 is intronic and the precise functional mechanism is not yet characterised, the evidence for specific interventions derives from the broader biology of MTHFD1L and mitochondrial one-carbon metabolism. The key targets are: supporting adequate formate supply to the cytoplasm (via B-vitamin cofactors that sustain the mitochondrial pathway), ensuring homocysteine does not accumulate, and monitoring markers of methylation capacity. Active-form B vitamins — particularly methylcobalamin (B12) and methylfolate rather than folic acid — bypass any upstream conversion bottlenecks and directly support the methionine re-methylation that keeps homocysteine in check.

Interactions

MTHFD1L operates upstream of MTHFR (rs1801133 and rs1801131). Individuals with reduced MTHFD1L output AND impaired MTHFR activity face a compounded reduction in methylation capacity: the mitochondrial pathway provides less formate to the cytoplasm, and the cytoplasmic pathway then converts less of that formate to methylfolate. The MTHFD1L rs6922269 variant is separately associated with active vitamin B12 levels and cardiovascular survival in coronary artery disease patients (PMID 24618918), confirming that multiple independent MTHFD1L variants influence metabolic outcomes. The folate transporter SLC19A1 (rs1051266) and methionine synthase reductase MTRR (rs1801394) are additional pathway partners where combined genetic burden amplifies one-carbon insufficiency.

Within the H1 haplotype of the MAPT gene — itself a well-established risk factor for neurodegenerative diseases involving tau protein — there exists a finer level of genetic variation. The rs242557 variant tags the H1c sub-haplotype, a distinct subset of H1 that carries substantially elevated risk for progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) compared to other H1 sub-haplotypes. This SNP adds resolution beyond the broad H1/H2 distinction captured by rs17649553, identifying individuals within the H1 majority who face the highest tau-related risk.

The Mechanism

Unlike the H1/H2 distinction — driven by a 900kb chromosomal inversion — H1c is a sub-haplotype within H1 defined by a specific combination of intronic variants including rs242557. The A allele at rs242557 tags the H1c configuration, which is associated with altered transcriptional regulation of the MAPT gene¹¹ tags the H1c configuration, which is associated with altered transcriptional regulation of the MAPT gene
The intronic variant likely affects splicing regulatory elements or transcription factor binding within the first large intron of MAPT.

A 2007 study found that the H1c haplotype specifically increases both the total level of MAPT transcripts and the proportion containing four microtubule-binding repeat domains (4R tau)²² A 2007 study found that the H1c haplotype specifically increases both the total level of MAPT transcripts and the proportion containing four microtubule-binding repeat domains (4R tau)
4R tau isoforms are the predominant component of pathological tau aggregates in PSP, CBD, and some forms of Alzheimer's disease. This mechanistic finding directly links the H1c genotype to the molecular pathology of 4R tauopathies: more total tau protein, with a higher fraction folded into the 4-repeat isoform that aggregates into neurofibrillary tangles and other tau deposits.

The Evidence

A 2017 meta-analysis of 82 case-control studies found that rs242557 (A allele) confers an odds ratio of 1.96 (95% CI 1.71–2.25) for PSP and 2.51 (95% CI 1.66–3.78) for CBD³³ A 2017 meta-analysis of 82 case-control studies found that rs242557 (A allele) confers an odds ratio of 1.96 (95% CI 1.71–2.25) for PSP and 2.51 (95% CI 1.66–3.78) for CBD
These effect sizes are among the largest identified for common variants in neurodegenerative disease risk. The CBD effect size (OR 2.51) is especially striking for a common variant, indicating that H1c roughly triples the risk of this rare condition compared to non-H1c individuals.

A 2015 GWAS of 219 CBD cases and 3,750 controls confirmed the H1c sub-haplotype marked by rs242557 as significantly associated with CBD risk (p = 7.91×10⁻⁶), and demonstrated that CBD and PSP share this genetic risk architecture⁴⁴ A 2015 GWAS of 219 CBD cases and 3,750 controls confirmed the H1c sub-haplotype marked by rs242557 as significantly associated with CBD risk (p = 7.91×10⁻⁶), and demonstrated that CBD and PSP share this genetic risk architecture
This shared genetics aligns with the clinical and neuropathological overlap between the two conditions.

For Alzheimer's disease, the H1c haplotype showed association with AD risk in two autopsy-confirmed case series (Myers et al., Human Molecular Genetics, 2005)⁵⁵ the H1c haplotype showed association with AD risk in two autopsy-confirmed case series (Myers et al., Human Molecular Genetics, 2005)
The AD association appears most relevant in APOE ε4 non-carriers, where MAPT haplotype becomes a more prominent risk factor. A 2007 quantitative trait study showed rs242557 drives the H1c association with cerebrospinal fluid tau levels in a dose-dependent manner (p = 0.002)⁶⁶ rs242557 drives the H1c association with cerebrospinal fluid tau levels in a dose-dependent manner (p = 0.002)
Higher CSF tau is a biomarker of neuronal injury and is elevated years before clinical Alzheimer's onset.

Practical Actions

The H1c genotype does not cause disease on its own — it modifies risk within a multifactorial landscape. Environmental and lifestyle factors that reduce tau hyperphosphorylation and aggregation are particularly relevant: avoiding head trauma, controlling metabolic risk factors for neurodegeneration (blood pressure, insulin resistance), and staying physically and cognitively active. No approved preventive pharmacotherapy targets tau pathology specifically in the presymptomatic period, but clinical trials of tau-targeting immunotherapies are ongoing.

Individuals carrying AA or AG genotypes at rs242557 who are also H1/H1 at rs17649553 face the combined burden of the broad H1 risk and the additional H1c refinement — neurological surveillance may be warranted if other risk factors (age, family history, additional genetic risk) are present.

Interactions

rs242557 adds independent risk stratification on top of the H1/H2 distinction captured by rs17649553. Nearly all individuals with the H1c sub-haplotype (A allele at rs242557) are also H1/H1 or H1/H2 at the broader haplotype level — these SNPs are in strong linkage disequilibrium but not perfectly correlated, so together they provide finer resolution. The rs2471738 variant (also listed among related SNPs) represents another H1 sub-haplotype marker with comparable effect sizes for PSP (OR 1.85) and CBD (OR 2.07), and may tag a partially overlapping but distinct risk subgroup.

In Alzheimer's disease, the MAPT H1c effect appears to interact with APOE status: the association is nominally significant in APOE ε4 carriers but may be more prominent in non-carriers, suggesting that H1c contributes to a distinct tauopathic path to AD independent of amyloid-driven mechanisms.

CYP3A4 is the single most consequential drug-metabolizing enzyme in the human body, responsible for the biotransformation of approximately 50% of all prescription medications¹¹ 50% of all prescription medications
The CYP3A subfamily collectively handles more clinical drugs than any other metabolic pathway. Found primarily in the liver and small intestine, CYP3A4 processes everything from immunosuppressants and statins to anticoagulants, antiepileptics, and targeted cancer therapies. When a variant reduces its activity — even modestly — the downstream effects ripple through a large fraction of pharmacological care.

The CYP3A4*18 allele, defined by the rs28371759 polymorphism (c.878T>G on the coding strand; p.Leu293Arg on the protein), substitutes a leucine with the bulkier, charged arginine at position 293. This position sits within a structurally important region of the enzyme, and multiple independent studies associate the variant with reduced catalytic activity²² multiple independent studies associate the variant with reduced catalytic activity
A 2024 systematic review of 23 studies in 2,177 epilepsy patients concluded that CYP3A4 rs28371759 is linked to reduced catalytic activity. The allele is rare globally — found in fewer than 1 in 10,000 European chromosomes — but reaches frequencies of 1–2% in East Asian populations³³ 1–2% in East Asian populations
Particularly elevated in Korean, Japanese, and Han Chinese cohorts, where it carries real clinical relevance.

The Mechanism

CYP3A4 is on the minus (coding) strand of chromosome 7. The c.878T>G change (plus-strand A>G at chr7:99,764,003 GRCh38) replaces leucine-293 with arginine. Leucine is a nonpolar, hydrophobic residue; arginine carries a positive charge and a large side chain. This radical physicochemical substitution is predicted to disrupt local protein folding⁴⁴ disrupt local protein folding
SIFT and PolyPhen-2 classify p.Leu293Arg as damaging/probably damaging in or near the enzyme's substrate-binding and heme-coordinating regions. The functional consequence is reduced intrinsic clearance of CYP3A4 substrates — carriers metabolize affected drugs more slowly than people with the common Leu293 allele.

The Evidence

Clinical evidence for rs28371759 comes primarily from East Asian cohorts, where the allele is most prevalent. A 2017 study of 183 northern Han Chinese patients⁵⁵ 2017 study of 183 northern Han Chinese patients
Liu et al. warfarin dosing study in patients with mechanical heart valve replacement found that CYP3A4 rs28371759 was independently associated with higher warfarin maintenance doses, contributing 2.5% of dose variability in multivariate regression. Since CYP3A4 plays a secondary role in warfarin S-enantiomer metabolism (CYP2C9 is primary), the variant's detection even in this context speaks to its functional impact.

A 2023 cohort study of 63 Thai NSCLC patients⁶⁶ 2023 cohort study of 63 Thai NSCLC patients
Majam et al. retrospective/prospective study of CYP450 polymorphisms and osimertinib outcomes identified rs28371759 among six SNPs significantly increasing adverse drug reaction incidence with osimertinib (a CYP3A4-metabolized EGFR inhibitor). A 2024 systematic review of carbamazepine pharmacogenetics⁷⁷ 2024 systematic review of carbamazepine pharmacogenetics
Riffi et al. 23 studies, 2,177+ epilepsy patients explicitly concluded that rs28371759 contributes to reduced catalytic activity affecting carbamazepine clearance.

Population surveys confirm the East Asian enrichment: Lee et al. 2013⁸⁸ Lee et al. 2013
CYP3A4 and CYP3A5 polymorphism screening across five ethnic groups found the highest minor allele frequency for CYP3A4*18 in the Korean cohort, and a 2024 Sri Lankan pharmacogenomics survey recorded a frequency of ~0.1%, consistent with the near-absence seen in South and European populations. Heart transplant pharmacokinetic models in Chinese cohorts have incorporated this variant as a significant covariate for tacrolimus clearance.

The overall evidence level is moderate: findings are replicated across independent cohorts and multiple drug classes, the biological mechanism is plausible, and the variant is analytically clean (rare, well-characterized missense change). However, no large prospective randomized trials or CPIC/DPWG guidelines exist specifically for this allele.

Practical Actions

For the vast majority of people worldwide, this variant is absent and no action is needed. For carriers — especially those of East Asian ancestry — the implications depend on which CYP3A4-metabolized drugs are prescribed.

For narrow therapeutic index drugs like tacrolimus, cyclosporine, and carbamazepine, reduced CYP3A4 activity means slower clearance: standard doses can produce supratherapeutic blood levels, raising toxicity risk. Therapeutic drug monitoring becomes especially important. For warfarin, the pharmacogenomics team should consider rs28371759 status alongside the dominant CYP2C9 and VKORC1 variants when modeling dose requirements.

The compounding effect of carrying rs28371759 alongside CYP3A4*22 (rs35599367) or CYP3A5*3/*3 (rs776746) is clinically important: these variants converge on the same metabolic pathway, and combined carriers may have substantially greater reductions in total CYP3A clearance than any single variant predicts.

Interactions

CYP3A4 rs28371759 interacts with the CYP3A metabolic axis:

CYP3A4*22 (rs35599367): This established decreased-function allele reduces CYP3A4 mRNA expression ~50%. Carriers of both rs28371759 (reduced protein function) and CYP3A4*22 (reduced protein quantity) would have severely diminished total CYP3A4 capacity. The combined recommendation for tacrolimus dosing should weight the established CYP3A4*22 guideline as primary, with rs28371759 as an additional signal for close monitoring.

CYP3A5*3 (rs776746): CYP3A5 non-expressers (*3/*3) already lack the CYP3A5 backup pathway. An rs28371759 carrier who is also CYP3A5*3/*3 (very common in Europeans) has reduced CYP3A4 activity with no CYP3A5 to compensate — these individuals are at greatest risk of accumulating tacrolimus, cyclosporine, or other CYP3A substrates to toxic levels.

CYP3A4*1G (rs2242480): This intronic variant reduces both CYP3A4 and CYP3A5 expression ~30% and is common in East Asian populations where rs28371759 also reaches actionable frequency. Co-occurrence of both alleles in the same individual would represent additive reductions in CYP3A metabolic capacity.

Your IRS1 (Insulin Receptor Substrate 1) gene encodes the first protein activated when insulin binds to its receptor on cell surfaces. Think of it as the ignition switch for your entire insulin signaling system¹¹ IRS1 is phosphorylated by the insulin receptor and then activates downstream pathways like PI3K/AKT that control glucose uptake, glycogen synthesis, and protein metabolism. This variant sits approximately 500 kb upstream of IRS1 and regulates how much IRS1 protein your muscle cells produce.

The Mechanism

The C allele at rs2943641 reduces IRS1 protein levels in skeletal muscle by approximately 30% and decreases insulin-stimulated phosphatidylinositol-3-OH kinase (PI3K) activity²² PI3K is the lipid kinase that IRS1 recruits after phosphorylation — it generates PIP3, which activates AKT to trigger GLUT4 translocation and glucose uptake. With less IRS1 protein available, insulin's signal gets dampened right at the source. Your pancreas compensates by secreting more insulin (hyperinsulinemia), but your muscles and liver remain relatively resistant to insulin's effects.

This creates a vicious cycle: higher insulin levels → more fat storage → more insulin resistance → even higher insulin. Breaking this cycle requires optimizing your diet to minimize insulin demand.

The Evidence

The original discovery GWAS³³ original discovery GWAS
Rung et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet, 2009 identified rs2943641 in 14,358 European participants with an odds ratio of 1.19 for type 2 diabetes per C allele (P = 9.3 × 10⁻¹²). Functional studies confirmed the C allele's association with reduced IRS1 protein and impaired PI3K activity in human muscle biopsies.

The POUNDS LOST trial⁴⁴ POUNDS LOST trial
Qi et al. IRS1 gene variation modifies insulin resistance response to weight-loss diets. Circulation, 2011 randomized 738 adults to four diets varying in macronutrient content for 2 years. At 6 months, CC carriers on the highest-carbohydrate diet (65% carbs, 20% fat) showed greater improvements in insulin resistance (HOMA-IR decreased by 0.27 vs 0.01 for CT/TT, P=0.009) and lost more weight (6.5 kg vs 4.5 kg, P=0.015). On the lowest-carbohydrate diet (35% carbs, 40% fat), the pattern reversed — non-CC carriers did better. This gene-diet interaction was significant (P<0.05) and persisted at 2 years for HOMA-IR (P=0.023).

A four-population vitamin D study⁵⁵ four-population vitamin D study
Powe et al. Circulating 25-hydroxyvitamin D, IRS1 variant rs2943641, and insulin resistance. Clin Chem, 2014 in 3,065 women found a striking gene-nutrient interaction: higher vitamin D levels (25(OH)D) reduced insulin resistance only in TT homozygotes, not in C carriers. For every 10 ng/ml increase in vitamin D, TT carriers saw HOMA-IR drop by 8% (pooled β = −0.008, P=0.004). This interaction was consistent across Boston Puerto Rican, Framingham Offspring, CARDIA, and Nurse's Health Study II cohorts and was female-specific.

Lipid effects⁶⁶ Lipid effects
Bacci et al. The type 2 diabetes and insulin-resistance locus near IRS1 is a determinant of HDL cholesterol and triglycerides. Atherosclerosis, 2011 examined 2,037 diabetic subjects and found each C allele decreased HDL cholesterol by 1 mg/dl (P=0.0045) and increased triglycerides by 6 mg/dl (P=0.018), independent of BMI.

Practical Implications

This variant creates a metabolic fork in the road. If you have the CC genotype, a higher-carbohydrate, lower-fat diet (Mediterranean or plant-based) improves insulin sensitivity more than a low-carb or ketogenic approach. The mechanism: lower dietary fat means less intramyocellular lipid accumulation, which would otherwise further impair the already-compromised insulin signaling.

For CT and TT genotypes, dietary flexibility is greater, though TT carriers uniquely benefit from optimizing vitamin D status.

Interactions

This variant interacts with dietary macronutrients in a sex-specific manner. A two-population study⁷⁷ A two-population study
Qi et al. Modulation by dietary fat and carbohydrate of IRS1 association with type 2 diabetes traits. Diabetes Care, 2013 found the protective T allele reduced T2D risk only in women with low carbohydrate intake and in men with low fat intake — suggesting men and women with this variant may need different macronutrient strategies.

The rs2943641 variant is in strong linkage disequilibrium with rs7578326 (both track together) and is independent of the IRS1 coding variant rs1801278 (G972R), which is 567 kb away.

For cancer risk, the SOS cohort⁸⁸ SOS cohort
Carlsson et al. The IRS1 rs2943641 variant and risk of future cancer among morbidly obese individuals. JCEM, 2013 found T allele carriers had lower cancer incidence, but only among individuals with BMI >40. This suggests the metabolic protection from lower insulin resistance translates to reduced cancer risk in the most insulin-resistant populations.

The orexin system is the brain's primary arousal engine. Two neuropeptides — orexin A and orexin B (also called hypocretin-1 and hypocretin-2) — are produced in a small cluster of neurons in the lateral hypothalamus and project widely across the brain. They act on two receptors: HCRTR1 (orexin receptor 1), which responds preferentially to orexin A, and HCRTR2 (orexin receptor 2, encoded by this gene), which binds both orexins with roughly equal affinity. HCRTR2 is expressed in the tuberomammillary nucleus, locus coeruleus, and dorsal raphe¹¹ tuberomammillary nucleus, locus coeruleus, and dorsal raphe
key brainstem and hypothalamic nuclei that drive wakefulness through histamine, norepinephrine, and serotonin release — making it a central hub of the wake-promoting circuit.

The biological importance of HCRTR2 for sleep-wake timing is underscored by animal genetics: narcolepsy in Doberman Pinschers was traced to a loss-of-function mutation in the HCRTR2 gene, and HCRTR2-knockout mice show disrupted sleep architecture with frequent wake-to-sleep transitions during the active period. In humans, orexin neuron loss (as in narcolepsy type 1) causes uncontrolled sleepiness and cataplexy, confirming the orexin-HCRTR2 axis as the neurological brake on inappropriate sleep onset during daytime.

rs35833281 is an intronic variant within HCRTR2 that has been identified as a genome-wide significant chronotype signal in multiple large GWAS. The C allele at this position is the morningness allele.

The Mechanism

rs35833281 sits within intron sequence of HCRTR2²² intron sequence of HCRTR2
intronic variants can influence gene expression through effects on splicing efficiency, transcription factor binding, or chromatin accessibility, and is in linkage disequilibrium with nearby functional variants in the HCRTR2 locus — including what Jones et al. 2019 describe as a fine-mapped missense variant in HCRTR2. Whether rs35833281 is itself causal or a tag SNP for a nearby functional change remains to be determined by fine-mapping studies.

The downstream biology, however, is clear: variation in HCRTR2 function modulates the strength or timing of the wake-drive signal mediated by the orexin system. A stronger or earlier orexin signal biases the circadian output toward earlier activity onset, producing the morningness phenotype. The additive nature of the chronotype GWAS signal is consistent with orexin system variants acting as quantitative modulators of arousal timing rather than on/off switches.

The Evidence

The strongest evidence comes from Jones et al. 2019³³ Jones et al. 2019
Genome-wide association analyses of chronotype in 697,828 individuals provides insights into circadian rhythms. Nature Communications, which identified 351 loci associated with morning preference. At rs35833281, the C allele reached genome-wide significance (p = 2×10⁻³¹) with OR ~1.05 for being a morning person — a small but highly replicable per-allele effect. The HCRTR2 locus was among those characterised as harbouring a fine-mapped missense variant, suggesting biological plausibility beyond statistical association. Activity-monitor data in 85,760 participants confirmed that individuals carrying the most morningness alleles across all loci sleep approximately 25 minutes earlier than those carrying the fewest. Mendelian randomisation in this same dataset demonstrated that morning preference causally lowers schizophrenia risk (OR 0.89, p = 0.004) and increases subjective well-being (0.04 SD, p = 5×10⁻⁵).

An earlier Jones et al. 2016⁴⁴ Jones et al. 2016
Genome-Wide Association Analyses in 128,266 Individuals Identifies New Morningness and Sleep Duration Loci. PLoS Genetics independently implicated the HCRTR2 region in chronotype, providing cross-cohort replication across UK Biobank and 23andMe datasets.

Lane et al. 2017⁵⁵ Lane et al. 2017
Genome-wide association analyses of sleep disturbance traits. Nature Genetics further identified a locus near HCRTR2 in a composite sleep trait GWAS (combining chronotype, insomnia symptoms, and daytime sleepiness in 112,586 individuals), suggesting the HCRTR2 signal extends across multiple dimensions of sleep-wake behaviour, not chronotype alone.

Practical Actions

The C allele at rs35833281 is a morningness allele — each copy nudges the biological clock slightly earlier. For CC homozygotes, both copies reinforce an early-rising tendency; for CG heterozygotes, the effect is present but attenuated. GG individuals carry neither copy and are somewhat more likely to be evening-types or have neutral chronotype.

The orexin system is also a target of pharmacological intervention. Dual orexin receptor antagonists (DORAs) such as suvorexant and lemborexant block HCRTR1 and HCRTR2 to promote sleep onset — a mechanism directly relevant to this genetic locus. Strong morning types with CC genotype who use sleep aids should be aware that DORAs target the same pathway their genotype influences. Evening types (GG) with insomnia or circadian misalignment may particularly benefit from chronotype-informed light-timing strategies.

Interactions

The orexin system interacts with the core circadian clock. Variants in CLOCK, BMAL1, PER2, and CRY1 affect the timing of the molecular clock in each cell; orexin receptor variants modulate how strongly the wake-promoting signal overrides the circadian sleep pressure at any given time. In principle, combinations of strong-clock variants (e.g., PER2 advanced sleep phase variants) with strong-orexin variants (CC at rs35833281) would compound morningness; weak-clock + GG combinations would compound eveningness. These interaction effects have not been formally studied in humans but are biologically plausible.

The GWAS Catalog lists rs35833281 in proximity to HCRTR2 at the same locus as rs2271933, a known HCRTR2 variant also studied in narcolepsy and cluster headache literature. Whether rs35833281 and rs2271933 tag the same functional variant or independent effects within HCRTR2 requires further fine-mapping.

Hepatic lipase (HL), encoded by the LIPC gene on chromosome 15, is a key enzyme in lipoprotein metabolism. It sits on liver sinusoid endothelium and acts as a lipase and ligand for lipoprotein uptake — hydrolyzing triglycerides and phospholipids in HDL and intermediate-density lipoproteins (IDL). Its best-known role is converting large, buoyant HDL2 particles into smaller, denser HDL3, a step that completes the reverse cholesterol transport¹¹ reverse cholesterol transport
the process by which excess cholesterol from peripheral tissues is ferried back to the liver for elimination or bile excretion cycle.

The rs3829462 variant causes a missense substitution at codon 356: phenylalanine (Phe, encoded by the C reference allele) to leucine (Leu, encoded by the common A allele). This is an unusual configuration — the GRCh38 reference carries the minor allele (C, ~2.6% globally), while the overwhelmingly common A allele (Leu356, ~97.4%) represents the normal population baseline.

The Mechanism

Phenylalanine and leucine are both nonpolar hydrophobic amino acids, which explains why computational tools (SIFT score 0.26, PolyPhen 0.137) classify this substitution as tolerated and benign. Position 356 lies in the C-terminal domain of hepatic lipase, a region involved in lipoprotein binding and heparin-sulfate proteoglycan interaction. The Phe→Leu change at this position preserves the hydrophobic character of the side chain, and no published functional studies have demonstrated that the C allele (Phe356) substantially alters enzyme catalysis, substrate affinity, or secretion.

Nonetheless, the variant falls within the LIPC gene, which encodes an enzyme whose activity is a primary determinant of HDL particle size distribution and triglyceride clearance from HDL. Full hepatic lipase deficiency (OMIM 151670²² OMIM 151670
autosomal recessive condition causing elevated HDL-C and hypertriglyceridemia due to impaired IDL and HDL remodeling) produces markedly elevated HDL-C with paradoxically elevated triglycerides and pro-atherogenic dyslipidemia. Heterozygous loss-of-function LIPC variants produce milder lipid phenotypes, including modestly elevated total cholesterol, LDL-C, and triglycerides, as Jacob et al.³³ Jacob et al.
Jacob EO et al. Phenotype in Individuals with Heterozygous Rare Variants in LIPC Encoding Hepatic Lipase. Atherosclerosis, 2024 showed in 46 heterozygous rare-variant carriers.

The Evidence

ClinVar classifies the A (Leu356) allele as Benign across three independent submissions (VCV000316673), citing allele frequency analysis showing the variant is far too common (~97.4%) to cause a rare Mendelian disease. The allele was identified in large population sequencing studies (Stahnke et al.⁴⁴ Stahnke et al.
Stahnke G et al. Human hepatic triglyceride lipase: cloning of the gene and expression/secretion of the recombinant enzyme. J Biol Chem, 1987) and documented as a natural variant in UniProt (P11150).

The broader LIPC literature establishes that reduced hepatic lipase activity has complex cardiovascular consequences. A study of normolipidemic Brazilian participants⁵⁵ study of normolipidemic Brazilian participants
Zago VHS et al. Lipase C, Hepatic Type -250A/G (rs2070895) Variant Enhances Carotid Atherosclerosis. Mol Genet Metab, 2020 found that a promoter variant reducing HL activity by 38% raised carotid plaque risk 3.9-fold despite higher HDL-C — because impaired HL produces dysfunctional HDL particles enriched in triglycerides and depleted in cholesteryl esters, less capable of effective reverse cholesterol transport.

For rs3829462 specifically, the evidence remains at the emerging level: the variant is catalogued, computationally predicted benign, and clinically classified as benign/uncertain. No dedicated functional or epidemiological studies have directly characterized the Phe356Leu substitution's effect on hepatic lipase activity or lipid phenotype.

Practical Actions

For the rare CC genotype (homozygous Phe356), the uncertainty warrants monitoring lipid subfractions — particularly HDL particle size distribution, triglycerides, and LDL particle count — to detect any functional HL impairment reflected in lipoprotein composition. Omega-3 fatty acids (EPA/DHA) can modulate hepatic lipase activity and triglyceride-rich lipoprotein clearance independently of genotype, making supplementation a reasonable adjunct.

For the AC heterozygote (~5% of people), the single C allele is unlikely to produce clinically meaningful HL impairment given the benign computational predictions and the high frequency of the A allele in the heterozygous state. Standard lipid monitoring remains appropriate.

Interactions

The biological effects of LIPC variants interact with CETP (rs708272, rs1800775), whose product transfers cholesteryl esters from HDL to LDL. The combination of reduced HL activity and altered CETP function can additively shift lipoprotein particle distributions. Isaacs et al.⁶⁶ Isaacs et al.
Isaacs A et al. Epistatic effect of CETP and LIPC on serum HDL-C. Arterioscler Thromb Vasc Biol, 2007 showed epistatic interaction between LIPC and CETP variants on HDL-C, with individuals homozygous for both variants showing the largest HDL elevations — yet without reduced atherosclerosis risk, highlighting that HL-driven HDL particle quality matters more than quantity.

LIPC promoter variants (rs1800588 C-514T, rs2070895 -250G/A) also affect HL expression and interact with adiposity and visceral fat distribution to modulate HDL subclass composition, particularly the HDL2/HDL3 ratio.

PPARγ¹¹ PPARγ
Peroxisome proliferator-activated receptor gamma: the master transcriptional regulator of adipogenesis and the primary target of thiazolidinedione insulin-sensitizing drugs such as pioglitazone controls whether pre-adipocytes mature into functional fat cells, how fat distributes between visceral and subcutaneous depots, and how sensitively peripheral tissues respond to insulin. The gene sits on chromosome 3p25 and is subject to tight transcriptional control by a set of regulatory elements embedded in its own introns. rs4684847 is an intronic variant at GRCh38 position chr3:12,344,838 that sits within one such regulatory region — a cis-acting element inside PPARG where the C allele has been shown to recruit PR domain²² PR domain
PR (PRDF1-RIZ) domain: a chromatin-modifying domain found in PRDM family proteins that binds DNA and recruits repressive histone methyltransferase complexes, reducing local gene transcription repressor proteins that dampen PPARG transcription in adipose tissue.

The Mechanism

The C allele at rs4684847 creates or strengthens a binding site within the PPARG intron for PR domain-containing proteins — likely members of the PRDM family, which include well-characterized transcriptional repressors such as PRDM16, PRDM3, and PRDM5. When these proteins occupy the cis-regulatory element, they recruit repressive histone methyltransferase³³ histone methyltransferase
Enzymes that add methyl groups to histones, compacting chromatin and silencing nearby genes — the molecular equivalent of turning down a dimmer switch on gene expression complexes that reduce PPARG transcript levels in adipose cells.

Lower PPARG activity has downstream consequences throughout adipose tissue biology. Reduced PPARγ impairs the maturation of pre-adipocytes into functional subcutaneous fat cells, shifting lipid storage toward visceral (intra-abdominal) depots. Visceral adipose tissue is metabolically active in a harmful way — it releases more inflammatory cytokines, is more resistant to insulin suppression of lipolysis, and is directly associated with metabolic syndrome⁴⁴ metabolic syndrome
A cluster of conditions — central obesity, elevated fasting glucose, dyslipidemia, and hypertension — that co-occur because of shared visceral adipose pathophysiology and increase the risk of cardiovascular disease and type 2 diabetes.

Because C is the reference (major) allele (~87–98% in most populations), TT homozygotes are rare globally (~3%). The T allele disrupts the repressor-binding element, allowing higher PPARG expression — the T allele is effectively the high-PPARγ, metabolically more favorable configuration despite being the minor allele.

The Evidence

A 9,364-person community-based cohort⁵⁵ 9,364-person community-based cohort
Gallicchio et al. Genetic polymorphisms of PPAR and the risk of cardiovascular morbidity and mortality in Washington County, Maryland. PPAR Research, 2008 found statistically significant age-adjusted associations between rs4684847 and both BMI and blood pressure at baseline in Caucasian adults. The association was with metabolic traits at a single time point rather than prospective cardiovascular events.

In a Chinese cohort study of 820 subjects⁶⁶ Chinese cohort study of 820 subjects
Lin et al. Association between peroxisome proliferator-activated receptors gene polymorphism and essential hypertension. Zhonghua Liu Xing Bing Xue Za Zhi, 2012, the T allele was associated with higher odds of essential hypertension after adjustment for age, sex, BMI, glucose, HDL-cholesterol, and diet: OR 1.42 (95% CI 1.04–1.94) for high blood pressure, OR 1.38 (1.03–1.92) for high SBP, and OR 1.37 (1.00–1.88) for high DBP. This T-allele hypertension association is plausibly explained by impaired vascular smooth-muscle PPARγ signaling rather than the adipose repression mechanism, since PPARγ also controls vascular tone and endothelial function.

Mortality data from a prospective cohort of 9,919 individuals⁷⁷ prospective cohort of 9,919 individuals
Gallicchio et al. SNPs in obesity-related genes and all-cause and cause-specific mortality. BMC Med Genet, 2009 found that TT homozygotes had significantly reduced all-cause mortality (RR 0.60, 95% CI 0.39–0.93) and cancer mortality (RR 0.22, 95% CI 0.06–0.90) compared to CC homozygotes. Although confidence intervals are wide owing to sparse TT counts, the direction is consistent with T allele carriers having lower PPARG-associated disease burden.

Additional studies in Chinese Han populations have linked rs4684847 to CRP levels⁸⁸ CRP levels
C-reactive protein: an acute-phase inflammatory marker produced by the liver in response to visceral adipose-derived cytokines; elevated CRP is a cardiovascular risk marker and lipoprotein(a) levels⁹⁹ lipoprotein(a) levels
Lp(a): a low-density lipoprotein particle with an extra apolipoprotein(a) tail; genetically elevated Lp(a) is an independent cardiovascular risk factor not addressed by statins (T allele carriers: −27.3 mg/L lower Lp(a), P < 0.05). A 2018 neurological study also found rs4684847 associated with cognitive performance scores in Parkinson's patients after correction for multiple comparisons, consistent with PPARγ's role¹⁰¹⁰ consistent with PPARγ's role
Yang et al. Expression of PGC-1α gene in peripheral blood leukocytes in Parkinson's disease. Parkinsonism Relat Disord, 2018 in neuroinflammation and mitochondrial function.

Evidence for this variant is rated moderate: it lacks a dedicated meta-analysis, the functional mechanism (PR domain recruitment) has been described but not exhaustively validated, and some associations are directionally inconsistent across different phenotypes and populations.

Practical Actions

For CC homozygotes — who represent the large majority — the main implication is that the PPARγ repressor pathway is fully operative, meaning adipogenesis and insulin sensitivity depend heavily on environmental modifiers. Dietary fat composition directly regulates PPARγ target gene expression: long-chain omega-3 fatty acids¹¹¹¹ long-chain omega-3 fatty acids
EPA and DHA act as direct PPARγ ligands, activating the receptor pathway when chromatin repression is not extreme EPA and DHA are PPARγ ligands that can partially bypass transcriptional suppression; saturated fatty acids downregulate the same target genes. Monitoring visceral fat accumulation through waist circumference and waist-to-hip ratio gives direct phenotypic feedback on whether PPARγ pathway suppression is expressing as central adiposity.

For CT heterozygotes, one allele reduces repressor binding, meaning partial relief of PPARγ suppression. The same dietary and monitoring strategies apply with somewhat lower urgency.

Interactions

rs4684847 operates within the same intron architecture as the well-characterized PPARG coding variants rs1801282 (Pro12Ala) and rs3856806 (His477His). These coding variants alter PPARG protein activity, while rs4684847 alters PPARG transcript levels. The combination of reduced transcription (rs4684847 CC) and altered receptor activity (rs1801282 CC Pro/Pro) likely compounds toward lower effective PPARγ signaling. The downstream intergenic variant rs4684854 may capture overlapping regulatory architecture via linkage disequilibrium. The intronic variant rs709158 and rs10865710 tag separate haplotype blocks with LDL-cholesterol and adiponectin associations; understanding the full PPARG regulatory haplotype requires reading all these variants together.

The glucocorticoid receptor (GR) encoded by NR3C1 is not a single protein but a family of isoforms generated by alternative splicing and translation initiation. The dominant active form, GRα, binds cortisol and drives the transcriptional programs that regulate inflammation, metabolism, immune function, and stress adaptation. A second isoform, GRβ, lacks the hormone-binding domain — it cannot bind cortisol, but it can heterodimerize with GRα and suppress its activity. The 9β variant (rs6198) shifts this balance: it stabilizes GRβ mRNA, producing more of the dominant-negative inhibitor and blunting the cell's response to cortisol signaling.

This is the opposite sensitivity pattern from the BclI variant (rs41423247)¹¹ BclI variant (rs41423247), which increases glucocorticoid sensitivity. Carriers of the 9β C allele experience relative glucocorticoid resistance — the same amount of cortisol produces a weaker biological response. This has downstream consequences for HPA axis regulation, inflammation control, blood pressure, mood, and the pace of cellular aging under chronic stress.

The Mechanism

The variant is an A-to-G substitution at position 3669 of exon 9β in the 3' untranslated region (3'UTR) of the NR3C1 transcript — reported as T-to-C on the plus strand. The wild-type AUUUA sequence motif destabilizes GRβ mRNA through AU-rich element-mediated decay²² AU-rich element-mediated decay
AUUUA pentamers in 3'UTRs recruit mRNA decay machinery that shortens poly(A) tails and accelerates transcript degradation.

The C allele converts AUUUA to GUUUA, disrupting this decay signal and stabilizing GRβ mRNA. More stable mRNA means more GRβ protein. Because GRβ heterodimerizes with GRα and competes for glucocorticoid response elements on DNA, elevated GRβ reduces transcriptional responses to cortisol without changing cortisol secretion itself. The result is a cell that is less able to act on cortisol signals — useful in contexts where you want to dampen immunosuppression (as seen in autoimmune protection against Graves' disease), but problematic when cortisol's anti-inflammatory and negative-feedback functions are needed.

The downstream effect³³ The downstream effect
Increased GRβ reduces GRα-mediated transrepression of inflammatory genes, tipping the balance toward pro-inflammatory gene expression even when cortisol is present.

The Evidence

The clearest window into rs6198's clinical significance comes from acute physiological stress. In a multicenter prospective cohort of 204 sepsis patients⁴⁴ In a multicenter prospective cohort of 204 sepsis patients
Sombetzki et al. Impact of glucocorticoid receptor polymorphism rs6198 on sepsis survival. Scientific Reports, 2025, the TT genotype (wild-type, standard GR sensitivity) was paradoxically more lethal: 30-day survival was 65% for TT carriers versus 82% for CC/CT carriers (HR 3.56, 95% CI 1.22–10.38, p = 0.02). This counterintuitive finding reflects that in the context of acute inflammatory overactivation, carrying more GRβ (which blunts cortisol's immunosuppressive effects) protects against the excessive anti-inflammatory response that can worsen sepsis outcomes.

The protective effect in Graves' disease follows the same logic. A case-control study of 792 individuals (384 patients and 408 controls)⁵⁵ A case-control study of 792 individuals (384 patients and 408 controls)
Nascimento et al. NR3C1 rs6198 variant and Graves' disease. Biomedicines, 2023 found that the TT genotype independently increased Graves' disease risk (OR 2.593, 95% CI 1.630–4.123, p < 0.0001), while TC and CC genotypes were protective. GRβ-mediated blunting of cortisol's immunosuppressive effects appears to maintain a more vigilant immune baseline that resists autoimmune thyroid triggering.

For chronic stress and mental health, however, the picture reverses. A Polish study of 514 bipolar disorder patients, 193 MDD patients, and 732 controls⁶⁶ A Polish study of 514 bipolar disorder patients, 193 MDD patients, and 732 controls
Szczepankiewicz et al. Glucocorticoid receptor polymorphism and depression. J Affect Disord, 2011 found rs6198 among three NR3C1 variants associated with major depressive disorder and with predominance of depression in bipolar disorder. When HPA axis feedback is chronically blunted by elevated GRβ, cortisol cannot effectively suppress its own release — contributing to the sustained elevated cortisol states seen in depression.

In Portuguese war veterans with combat exposure⁷⁷ In Portuguese war veterans with combat exposure
Castro-Vale et al. NR3C1 9β SNP and PTSD. Healthcare, 2021, the G allele (C on plus strand) showed OR 3.58 (95% CI 1.09–11.80, p = 0.036) for lifetime PTSD under a dominant model. Offspring of G-allele carrier veterans also had significantly lower hair cortisol concentrations (measured in 69 veterans' offspring), consistent with chronically reduced glucocorticoid signaling efficiency rather than reduced cortisol secretion.

The blood pressure connection was documented in the GENOA family study⁸⁸ was documented in the GENOA family study
Chung CC et al. Glucocorticoid receptor gene variant and blood pressure. J Clin Endocrinol Metab, 2009: rs6198 A/G (T/C on plus strand) was significantly associated with multiple blood pressure measures in European-Americans. Glucocorticoid signaling is integral to vascular tone regulation; blunted GR activity through elevated GRβ shifts vascular responses.

Practical Implications

The 9β variant creates a specific pattern: standard or lower glucocorticoid sensitivity under chronic conditions, but better preservation of immune surveillance under acute inflammatory challenge. For longevity and healthy aging, this has conflicting implications.

On the protective side, relative glucocorticoid resistance may reduce the cortisol-mediated acceleration of cellular aging that is otherwise a major driver of biological age advancement. Cortisol responsivity to acute stress is independently associated with telomere attrition⁹⁹ Cortisol responsivity to acute stress is independently associated with telomere attrition
Steptoe A et al. Cortisol responses and leukocyte telomere attrition. J Clin Endocrinol Metab, 2017 — in a cohort of 411 adults followed for 3 years, cortisol responders showed telomere shortening equivalent to approximately 2 additional years of biological aging. Attenuated cellular sensitivity to cortisol (as produced by GRβ elevation) could theoretically reduce this stress-accelerated aging.

On the vulnerability side, the same blunted HPA feedback increases susceptibility to sustained depressive episodes and chronic low-grade inflammation. Both chronic depression and low-grade inflammation are major contributors to aging-associated morbidity — they just operate through different pathways than the cortisol hypersensitivity seen with BclI.

Interactions

The 9β variant operates in concert with other NR3C1 variants and HPA axis regulators. The BclI polymorphism (rs41423247) increases glucocorticoid sensitivity — the opposite direction — so a person carrying both the BclI G allele (increased GRα sensitivity) and the 9β C allele (increased GRβ expression) faces competing intracellular signals whose net effect requires haplotype-level analysis rather than single-SNP interpretation.

The FKBP5 variant (rs1360780) is particularly relevant: FKBP5 encodes a co-chaperone that normally prevents GR from translocating to the nucleus until cortisol is bound. The FKBP5 risk allele slows cortisol-induced negative feedback. When combined with the 9β C allele's blunting of GR signaling through elevated GRβ, these two variants may compound to create a severely impaired HPA axis recovery from stress, relevant to PTSD and depression vulnerability.

An interaction between rs9470080 of FKBP5 and rs6198 of NR3C1 in modulating major depressive disorder risk has been directly documented.

The BCO1 gene (formerly called BCMO1) encodes beta-carotene 15,15'-monooxygenase¹¹ beta-carotene 15,15'-monooxygenase
The enzyme that cleaves one molecule of beta-carotene into two molecules of retinal, which is then converted to retinol (vitamin A), the key enzyme responsible for converting beta-carotene from plant foods into retinol -- the form of vitamin A your body actually uses. This single enzymatic step is the only route by which dietary carotenoids from carrots, sweet potatoes, spinach, and other orange and green vegetables become biologically active vitamin A.

The rs7501331 variant causes an alanine-to-valine substitution at position 379 of the BCO1 protein. Carriers of the T allele produce a less efficient enzyme, meaning more beta-carotene passes through unconverted. This is one of two coding variants in BCO1 (alongside rs12934922²² rs12934922
R267S, the other common BCMO1 coding variant with a 42% minor allele frequency) that together explain much of the genetically determined variation in beta-carotene conversion efficiency across the population.

The Mechanism

BCO1 is a non-heme iron oxygenase³³ non-heme iron oxygenase
It requires iron as a cofactor and molecular oxygen to cleave the central 15,15' double bond of beta-carotene expressed primarily in intestinal enterocytes and the liver. It cleaves beta-carotene symmetrically at the central 15,15' double bond, producing two molecules of retinal⁴⁴ retinal
Also called retinaldehyde; this is subsequently reduced to retinol (vitamin A) by retinal reductase. The Ala379Val substitution occurs within the catalytic domain, subtly altering the enzyme's active site geometry and reducing its turnover rate.

The body has a feedback mechanism: when retinol levels are adequate, an intestinal transcription factor⁵⁵ intestinal transcription factor
ISX (intestine-specific homeobox) represses BCO1 transcription when retinoic acid levels are sufficient downregulates BCO1 expression to prevent vitamin A toxicity. In people with reduced BCO1 activity, this feedback loop still operates, but the baseline conversion capacity is lower, meaning less vitamin A is produced from a given amount of dietary beta-carotene even before feedback suppression kicks in.

The Evidence

The landmark 2009 study by Leung et al.⁶⁶ 2009 study by Leung et al.
Leung WC et al. Two common single nucleotide polymorphisms in the gene encoding beta-carotene 15,15'-monoxygenase alter beta-carotene metabolism in female volunteers. FASEB J, 2009 identified rs7501331 (A379V) and rs12934922 (R267S) as the two common coding variants responsible for the "poor converter" phenotype. Female volunteers carrying the 379V allele showed a 32% reduction in the retinyl palmitate-to-beta-carotene ratio after a pharmacological beta-carotene dose (P = 0.005). Those carrying both variant alleles (379V + 267S) showed a 69% reduction (P = 0.001). In vitro, the double mutant enzyme had 57% lower catalytic activity (P < 0.001).

Carriers also had dramatically higher fasting plasma beta-carotene: +160% for 379V carriers and +240% for double carriers. This accumulation of unconverted beta-carotene is the biochemical signature of poor converter status and can manifest as carotenodermia⁷⁷ carotenodermia
A harmless yellowing of the skin, especially the palms and soles, caused by excess circulating carotenoids in extreme cases.

A large study in 2,344 women⁸⁸ large study in 2,344 women
Hendrickson SJ et al. BCO1 SNPs in relation to plasma carotenoid and retinol concentrations in women of European descent. Am J Clin Nutr, 2012 of European descent confirmed that BCO1 genetic variants predict plasma carotenoid levels and can serve as surrogate markers for carotenoid exposure in epidemiological studies.

In Filipino children and adolescents, Zumaraga et al. (2022)⁹⁹ Zumaraga et al. (2022)
Zumaraga MPP et al. Genotype effects on beta-carotene conversion to vitamin A. Food Nutr Bull, 2022 found the A379V T allele was inversely associated with vitamin A status in a cohort of 693 subjects, highlighting the relevance of this variant for populations that depend heavily on plant-based provitamin A sources.

Borel et al. (2011)¹⁰¹⁰ Borel et al. (2011)
Borel P et al. Genetic variants in BCMO1 and CD36 are associated with plasma lutein concentrations and macular pigment optical density. Ann Med, 2011 found that rs7501331 genotype also affects macular pigment optical density and plasma lutein levels, suggesting BCO1 variants influence the metabolism of multiple carotenoids beyond beta-carotene alone.

Practical Implications

The clinical relevance of rs7501331 depends heavily on dietary context. For people eating a mixed diet with adequate preformed vitamin A from eggs, dairy, fish, and liver, reduced beta-carotene conversion is largely inconsequential -- the body gets retinol directly from animal sources regardless of BCO1 efficiency.

The variant becomes clinically meaningful for vegans, vegetarians, and anyone relying primarily on plant sources for vitamin A. A person with two T alleles who eats no animal products may struggle to maintain adequate retinol status from beta-carotene alone, particularly if their diet is also low in fat (since beta-carotene absorption requires dietary fat).

Signs of suboptimal vitamin A status include dry eyes, night vision difficulty, dry skin, and impaired immune function. A serum retinol test can clarify actual status regardless of genotype.

Interactions

The most important interaction is with rs12934922 (R267S), the other common BCO1 coding variant. Individuals carrying T alleles at both rs7501331 and rs12934922 have compound poor converter status with up to 69% reduced beta-carotene conversion -- far exceeding the effect of either variant alone. The R267S variant has a higher minor allele frequency (42%) than A379V (24%), making the double-carrier combination relatively common. In the Leung et al. study, about 7-8% of the population carried both variant alleles.

This compound interaction is well-documented and represents one of the clearest gene-gene interactions in nutritional genomics. For double carriers who are vegan or vegetarian, preformed vitamin A supplementation (retinyl palmitate or retinol) or regular consumption of retinol-rich foods becomes particularly important.